Aerosol deposition in cystic fibrosis using an aerosol conservation device and a conventional jet nebulizer
- 1 February 1994
- journal article
- clinical trial
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 30 (1) , 65-67
- https://doi.org/10.1111/j.1440-1754.1994.tb00569.x
Abstract
The deposition of technetium radiolabelled aerosol within the lungs of 12 stable cystic fibrosis patients (mean age 12.7 years) was compared using the Acorn nebulizer and mouthpiece alone, and the Acorn nebulizer attached to the Mizer Aerosol Conservation Device (MACD). The total activity delivered to the patient using the MACD was 11.1% (\pm7.8% s.d.) of the initial dose, compared to 5.8% (\pm4.2% s.d.) with the nebulizer and mouthpiece alone (PP<0.05). No significant correlation was found between aerosol deposition and pulmonary function. The Mizer Aerosol Conservation Device significantly increases both total intrapulmonary aerosol deposition and peripheral aerosol distribution.Keywords
This publication has 4 references indexed in Scilit:
- IMPROVING THE EFFICIENCY OF DRUG ADMINISTRATION WITH JET NEBULISERSThe Lancet, 1988
- Quantitative Deposition of Aerosolized Gentamicin in Cystic FibrosisAmerican Review of Respiratory Disease, 1987
- Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosisThe Journal of Pediatrics, 1987
- Improvement of pressurised aerosol deposition with Nebuhaler spacer device.Thorax, 1984